Syeda Rida Zainab, Jehan Zeb Khan, Mujeeb Ur Rehman, Fawad Ali Shah, Muhammad Khalid Tipu
{"title":"Effect of Bacillus clausii in attenuating symptoms of DSS-induced ulcerative colitis by modulating NFkB pathway and oxidative stress in mice","authors":"Syeda Rida Zainab, Jehan Zeb Khan, Mujeeb Ur Rehman, Fawad Ali Shah, Muhammad Khalid Tipu","doi":"10.1111/1440-1681.70004","DOIUrl":null,"url":null,"abstract":"<p>Ulcerative colitis (UC) is a condition characterized by inflammation and ulcer formation in the colon and rectum due to genetic and environmental factors. It is a common condition, with a global prevalence rate exceeding 0.3%. Current treatments have limited efficacy and can cause unwanted side effects, leading to a high recurrence rate and reduced quality of life for patients. This study suggests that <i>Bacillus clausii</i> has a beneficial role in reducing intestinal inflammation and relieving colitis symptoms in mice. The study aimed to examine <i>B. clausii</i>'s potential to reduce the progression and pathogenesis of dextran sulphate sodium (DSS)–induced UC. <i>Bacillus clausii</i> was administered to mice as a pre-treatment, post-treatment and adjunct treatment with sulfasalazine for 14 days. The study found that <i>B. clausii</i> effectively reduced the severity of colitis in mice when used preventatively. Administering <i>B. clausii</i> after the onset of colitis also effectively alleviated symptoms. Combining <i>B. clausii</i> with standard sulfasalazine as adjunct therapy was more effective in reducing intestinal inflammation than using a single therapy alone. <i>B. clausii</i> has shown the potential to prevent colon damage and decrease the likelihood and severity of the disease. Immunohistochemistry results revealed a decrease in the expression of pro-inflammatory cytokines such as IL-1β, TNF-α and NFkB in colon tissue. Additionally, mice that received <i>B. clausii</i> showed a significant increase in anti-oxidant levels and improved haematological markers. In conclusion, it must be emphasized that <i>B. clausii</i> possesses the potential to alleviate the symptoms of UC.</p>","PeriodicalId":50684,"journal":{"name":"Clinical and Experimental Pharmacology and Physiology","volume":"51 12","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Pharmacology and Physiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1440-1681.70004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Ulcerative colitis (UC) is a condition characterized by inflammation and ulcer formation in the colon and rectum due to genetic and environmental factors. It is a common condition, with a global prevalence rate exceeding 0.3%. Current treatments have limited efficacy and can cause unwanted side effects, leading to a high recurrence rate and reduced quality of life for patients. This study suggests that Bacillus clausii has a beneficial role in reducing intestinal inflammation and relieving colitis symptoms in mice. The study aimed to examine B. clausii's potential to reduce the progression and pathogenesis of dextran sulphate sodium (DSS)–induced UC. Bacillus clausii was administered to mice as a pre-treatment, post-treatment and adjunct treatment with sulfasalazine for 14 days. The study found that B. clausii effectively reduced the severity of colitis in mice when used preventatively. Administering B. clausii after the onset of colitis also effectively alleviated symptoms. Combining B. clausii with standard sulfasalazine as adjunct therapy was more effective in reducing intestinal inflammation than using a single therapy alone. B. clausii has shown the potential to prevent colon damage and decrease the likelihood and severity of the disease. Immunohistochemistry results revealed a decrease in the expression of pro-inflammatory cytokines such as IL-1β, TNF-α and NFkB in colon tissue. Additionally, mice that received B. clausii showed a significant increase in anti-oxidant levels and improved haematological markers. In conclusion, it must be emphasized that B. clausii possesses the potential to alleviate the symptoms of UC.
溃疡性结肠炎(UC)是一种因遗传和环境因素导致结肠和直肠发炎并形成溃疡的疾病。它是一种常见病,全球发病率超过 0.3%。目前的治疗方法疗效有限,而且会产生不必要的副作用,导致高复发率,降低患者的生活质量。这项研究表明,枯草芽孢杆菌在减轻肠道炎症和缓解小鼠结肠炎症状方面具有有益作用。该研究旨在探讨克劳氏芽孢杆菌在减少右旋糖酐硫酸钠(DSS)诱导的多发性结肠炎的进展和发病机制方面的潜力。小鼠在治疗前、治疗后和磺胺沙拉嗪的辅助治疗中分别服用了克劳氏芽孢杆菌14天。研究发现,预防性使用克劳斯氏芽孢杆菌能有效减轻小鼠结肠炎的严重程度。在结肠炎发病后服用克劳氏菌也能有效缓解症状。在减少肠道炎症方面,将鲍鱼和标准的磺胺沙拉嗪结合起来作为辅助疗法比单独使用一种疗法更有效。克劳斯蝙蝠蛾具有预防结肠损伤、降低患病几率和严重程度的潜力。免疫组化结果显示,结肠组织中IL-1β、TNF-α和NFkB等促炎细胞因子的表达量有所下降。此外,接受 B. clausii 治疗的小鼠的抗氧化剂水平显著提高,血液指标也有所改善。总之,必须强调的是,克劳斯蚕豆具有缓解UC症状的潜力。
期刊介绍:
Clinical and Experimental Pharmacology and Physiology is an international journal founded in 1974 by Mike Rand, Austin Doyle, John Coghlan and Paul Korner. Our focus is new frontiers in physiology and pharmacology, emphasizing the translation of basic research to clinical practice. We publish original articles, invited reviews and our exciting, cutting-edge Frontiers-in-Research series’.